Thyroid hormone plus dual-specificity phosphatase-5 siRNA increases the number of cardiac muscle cells and improves left ventricular contractile function in chronic doxorubicin-injured hearts

Conclusion: RNA therapies are showing great potential. Importantly, a GMP compliant in vivo-jetPEI system for delivery of siRNA is already in use in humans, as is T3. Given these considerations, our findings provide a potentially highly translatable strategy for addressing doxorubicin cardiomyopathy, a currently untreatable condition.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Lin Tan, Nikolay Bogush, Emmen Naqvi, John W. Calvert, Robert M. Graham, W. Robert Taylor, Nawazish Naqvi, Ahsan Husain Tags: Research Paper Source Type: research